Month: March 2021
Excerpt from the Press Release: SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) — Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 2 clinical trial of OTO-313 in patients with unilateral tinnitus. The randomized, double-blind, placebo-controlled Phase 2 study will enroll approximately…
Read More
Excerpt from the Article: Meissa Vaccines’ intranasal live attenuated chimeric virus-based vaccine for SARS-CoV-2 (and its variants) recently was cleared for Phase I trials, which will start at the end of March. Unlike other live attenuated virus vaccines, it employs codon deoptimization to evoke a stronger-than-usual immune response. If approved, it holds the potential of…
Read More
Excerpt from the Article: Simultaneous use of a deep-learning based detection (DLD) system improves a radiologist’s accuracy in identifying major abnormalities on chest X-rays, a new study has found. While the efficacy of artificial intelligence (AI) algorithms as a second reader has been well established in previous studies, providers included in those investigations have read…
Read More
Excerpt from the Press Release: SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today updated positive results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). This ongoing study (MSC-COV-101) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy of COVI-MSCs administered every other day for…
Read More
Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization. This interim safety and efficacy analysis was based on 32,449 participants accruing 141 symptomatic cases of COVID-19. The trial had…
Read More
Excerpt from the Press Release: CARLSBAD, Calif., March 22, 2021 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it has entered into an agreement to acquire all of the issued and outstanding shares of 7D Surgical, Inc.,…
Read More
On March 23rd, we hosted our virtual networking meeting focused on the complexities of imaging based clinical trials. Heather and Christopher along with their guest Malachi Bierstein of ScienceMedia facilitated a wonderful presentation and discussion around the benefits of effective site training and it’s impact on clinical trial performance! Thank you to everyone who participated…
Read More
Excerpt from the Press Release: PARIS and CAMBRIDGE, Mass., March 22, 2021 (GLOBE NEWSWIRE) — BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“BIOPHYTIS” or the “company”), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients…
Read More
Excerpt from the Article: A radiology workflow artificial intelligence (AI) solution from RADLogics can help providers truncate their turn-around time for COVID-19 detection cases by up to 30 percent, according to a recently released study. According to a clinical trial conducted at the Moscow Center for Diagnostics & Telemedicine, employing this AI solution to evaluate…
Read More
Excerpt from the Press Release: SAN DIEGO, March 18, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that the first patient has been treated in its Phase 1b Amyloid Light Chain (AL) Amyloidosis study of STI-6129, an ADC which uses STI-5171, a fully human monoclonal antibody (mAb) from Sorrento’s G-MAB™ library.…
Read More